1. Introduction
===============

Danggui Buxue Tang (DBT) is a Traditional Chinese Medicine (TCM) formula primarily used to treat symptoms associated with menopause in women. It is believed to invigorate 'Qi' (vital energy) and nourish the 'Blood' (body circulation) \[[@B1-molecules-19-05650]\]. Nowadays, it is commonly used in China as an efficacious medicinal prescription and a healthy food supplement. Pharmacological studies have found that DBT promotes hematopoietic function \[[@B2-molecules-19-05650],[@B3-molecules-19-05650]\], regulates blood lipid and anti-inflammatory activities in diabetic atherosclerosis \[[@B4-molecules-19-05650],[@B5-molecules-19-05650]\], anti-fibrosis effects \[[@B6-molecules-19-05650]\], prevents osteoporosis \[[@B7-molecules-19-05650],[@B8-molecules-19-05650]\], and increases anti-oxidation activity as well as immune response \[[@B9-molecules-19-05650]\]. According to its original formula, DBT comprises Radix Astragali (RA) and Radix Angelicae Sinensis (RAS) (5:1, w/w). More recently, Radix Hedysari (RH) has been used to replace RA. Thus, in current clinical applications, DBT is prescribed in two forms: RA:RAS (5:1) (called DBT1), and RH:RAS (5:1) (called DBT2) \[[@B1-molecules-19-05650],[@B10-molecules-19-05650]\].

The plants RA and RH belong to the same botanical family but different genus, and have long been widely used as the same crude herb in DBT \[[@B1-molecules-19-05650]\]. This is always a question of whether RH can replace RA in the DBT decoction. Chemically, RA-containing DBT showed higher amounts of calycosin-7-*O*-*β*-[d]{.smallcaps}-glucoside, ferulic acid, ononin, calycosin, astragaloside IV, astragaloside III, and *Z*-ligustilide. Only formononetin was higher in RH-containing DBT. In parallel, the estrogenic, osteogenic and erythropoetic effects of RA-containing DBT1 showed better activities than that of RA-containing DBT2 \[[@B1-molecules-19-05650]\]. So far, the chemical differences between DBT1 and DBT2 has not been investigated. Therefore, we designed a systematic comparison of the chemical ingredients of DBT1 and DBT2.

Two experiments were designed, including thorough elucidation of the chemical profiles of DBT1 and DBT2 crude extracts and illumination of the metabolites of DBT1 and DBT2 after being administrated to rats. The chemical profiles of the two DBTs were compared by determining the total ion chromatogram(TIC) and the multistage mass spectra (MS^n^) from HPLC-DAD-ESI-IT-TOF-MS^n^. Subsequently, DBT1 and DBT2 were identified and compared on the basis of the TIC and the MS^n^ \[[@B11-molecules-19-05650]\]. The results will be provide a solid evidence to understand the chemical profiles of the two different versions of DBT.

2. Results and Discussion
=========================

2.1. Optimization the Conditions of HPLC and Mass Spectrometry
--------------------------------------------------------------

In order to obtain desirable HPLC and mass spectrometry chromatograms, the procedures for preparation of the urine samples and crude extracted samples of the two DBTs were optimized in terms of the extraction solvents and extraction times. Methanol and acetonitrile were initially selected as the extraction solvents, but methanol is less poisonous and produced almost the same chromatograms as acetonitrile, so it was applied as the final extraction solvent. For comparison, different columns (Phenomenex RP C~18~, Agilent RP C~18~) were tested for sample separation, and Phenomenex RP C~18~ gave the best chromatographic resolution. The column was eluted with a gradient mobile phase that consisted of water-formic acid (100:0.1, v/v) (A), acetonitrile (B) and at a flow rate of 1.0000 mL/min, in addition, 0.1% (v/v) formic acid was added to improve the mass spectrometry ionization efficiency and enable symmetric peak shapes \[[@B12-molecules-19-05650]\]. Both the positive ion (PI) and negative ion(NI) modes were tested for the experiment. Since MS and MS^n^ fragmentations gave more information about the isoflavones in PI mode but about saponins in NI mode, the analysis was simultaneously conducted in both PI and NI mode.

2.2. The Identification and Analysis of 19 Reference Compounds
--------------------------------------------------------------

Nineteen reference compounds which might represent the major structural types of the DBTs were analyzed. The characteristic fragment ions of 19 references are very useful for determining the structural skeleton and the substitution patterns of those related compounds in two DBTs. Their high resolution mass spectra (HRMS) data are summarized (see [Table 1](#molecules-19-05650-t001){ref-type="table"} and [Supplementary: pages S2--S8](#app1-molecules-19-05650){ref-type="app"}). The base peak chromatograms (BPCs) detected in NI and PI mode were recorded (see [Figure 1](#molecules-19-05650-f001){ref-type="fig"}a). Furthermore, the structure of 19 reference compounds were shown ([Figure 1](#molecules-19-05650-f001){ref-type="fig"}b) \[[@B11-molecules-19-05650],[@B13-molecules-19-05650]\].

According to our preliminary research, there three main types of isoflavonoids are found in Radix Astragali which were named as **a**: isoflavone (T1, T2, T5, T6, and T8), **b**: isoflavan (T4, T7, and T10) and c: pterocarpan (T3, and T9) \[[@B11-molecules-19-05650],[@B13-molecules-19-05650],[@B14-molecules-19-05650],[@B15-molecules-19-05650]\]. To facilitate the structural identification of the isoflavonoids in the DBTs, the fragmentation behaviors of the three types of isoflavonoids were analyzed, which might represent the major structural types. We first studied the MS^n^ fragmentation behaviors in PI and NI mode, and found that the fragmentation behaviors in PI mode could give more information about the structure than in NI modes. Then we elucidated the structure of the three types of isoflavonoids mostly from the PI mass spectra.

Isoflavone had the characteristic fragment ions ^5^B^+^-2H, ^0,3^B^+^-2H, ^5^A^+^-2H, ^1,3^A^+^-2H, ^3,4^A^+^-2H, *etc.*, isoflavan had the characteristic fragment ions ^5^B^+^-2H, ^5^A^+^-2H, ^1,3^A^+^-2H, *etc.*, and pterocarpan had the characteristic fragment ions ^6,7^B^+^-2H, ^1,4^B^+^-2H, ^3,4^A^+^-2H, ^5,6^A^+^-2H, *etc.*, based on MS^2^ and MS^3^ spectra by HPLC-DAD-ESI-IT-TOF-MS^n^ (see [Figure 2](#molecules-19-05650-f002){ref-type="fig"}).

For example, we identified the characteristic malonate-glucose-, acetyl-glucose- and glucose-binding ingredients with a neutral loss of 248 Da, 204 Da, and 162 Da, otherwise, glucuronide metabolites with a neutral loss of (−176 Da) and sulfated metabolites with a neutral loss of (−80 Da) from the molecular ion peaka in the MS^2^ spectra \[[@B13-molecules-19-05650],[@B16-molecules-19-05650],[@B17-molecules-19-05650]\].

molecules-19-05650-t001_Table 1

###### 

The fragment ions of 19 kinds of reference compounds by HPLC-DAD-ESI-IT-TOF-MS^n^.

  NO.        T~R~ (min)   \[M+H\]^+^      \[M−H\]^−^    Predicted Formula   Fragment Ions Da                      Error (ppm)   The Name of the Reference Compounds
  ---------- ------------ --------------- ------------- ------------------- ------------------------------------- ------------- ---------------------------------------------------------------------------
  1(T1)      28.595       447.1290                      C~22~H~22~O~10~     447,285,270,225                       0.89          Calycosin-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside
  2(AW)      29.162                       193.0501      C~10~H~10~O~4~      193,178,134                           −2.59         Ferulic acid
  3(T2)      34.545                       431.1326      C~22~H~22~O~9~      431,269,253,237,213,197,163,134,107   −2.55         Ononin
  4(T3)      36.038       485.1400        \[M+Na\]^+^   C~23~H~26~O~10~     485,463,323,301                       −3.71         Astrapterocarpan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside
  5(T4)      36.785       487.1574        \[M+Na\]^+^   C~23~H~28~O~10~     487,303,167                           −0.21         Astraisoflavan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside
  6(T5)      38.055       285.0754                      C~16~H~12~O~5~      285,270,253,225,197,137               −1.40         Calycosin
  7(T6)      40.123       473.1432                      C~24~H~24~O~10~     473,269                               −2.11         6\'\'-*O*-acetyl-ononin
  8(T7)      41.942       529.1691        \[M+Na\]^+^   C~25~H~30~O~11~     529,507,303                           2.08          6\'\'-*O*-acetyl-astraisoflavan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside
  9(T8)      45.410       269.0795                      C~16~H~12~O~4~      269,270,237                           −4.83         Formononetin
  10(T9)     46.062       301.1076                      C~17~H~16~O~5~      301,271,251,167,151,134               1.66          (6aR,11aR)-3-hydroxy-9,10-dimethoxypterocarpan; Astrapterocarpan
  11(T10)    46.655       303.1213                      C~17~H~18~O~5~      303,181,167,149,123                   −4.62         (3R)-7,2\'-dihydroxy-3\',4\'-dimethoxyisoflavan; Astraisoflavan
  12(GⅤ)     41.110       \[M+HCOO\]^−^   991.5156      C~47~H~78~O~19~     991,783,397                           3.73          Astragaloside Ⅴ
  13(GⅣ)     42.775       \[M+HCOO\]^−^   829.4615      C~41~H~68~O~14~     829,783,621,489,383                   2.89          Astragaloside Ⅳ
  14(GⅢ)     43.410       \[M+HCOO\]^−^   829.4585      C~41~H~68~O~14~     829,783,651,489                       −0.72         Astragaloside Ⅲ
  15(GⅡ)     44.628       \[M+HCOO\]^−^   871.4693      C~43~H~70~O~15~     871,765,717                           −0.46         Astragaloside Ⅱ
  16(GⅠ)     50.525       \[M+HCOO\]^−^   913.4802      C~45~H~72~O~16~     913,867,807                           0.00          Astragaloside Ⅰ
  17(HHQC)   51.855       513.3550        \[M+Na\]^+^   C~30~H~50~O~5~      513,515,405,229                       0.00          Cycloastragenol(HHQC)
  18(ZL)     55.477       191.1056                      C~12~H~14~O~2~      191,173,117                           −5.76         *Z*-ligustilide
  19(EL)     58.102       191.1066                      C~12~H~14~O~2~      191,173                               −0.52         *E*-ligustilide

![(**a**) LC-MS chromatogram of 19 reference compounds in PI (**1BPC**) and NI (**4BPC**) mode. (**b**) The chemical structures of 19 reference compounds.](molecules-19-05650-g001){#molecules-19-05650-f001}

![The bond cleavage pathways of the three types of isoflavonoids in RA.](molecules-19-05650-g002){#molecules-19-05650-f002}

2.3. Profiling and Identifying Chemical Compounds of the Two Crude Extracts (DBT1, and DBT2) by HPLC-DAD-ESI-IT-TOF-MS^n^
-------------------------------------------------------------------------------------------------------------------------

### 2.3.1. Identification of the Chemical Profiles of DBT1 by HPLC-DAD-ESI-IT-TOF-MS^n^

The HRMS data of these identified compounds are summarized (see [Table 2](#molecules-19-05650-t002){ref-type="table"} and [Supplementary: pages S9--S35](#app1-molecules-19-05650){ref-type="app"}). The BPCs detected in PI (**1BPC**) and NI (**4BPC**) mode were also recorded ([Figure 3](#molecules-19-05650-f003){ref-type="fig"}a) \[[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B19-molecules-19-05650]\].

By comparing the fragment ions and retention times and based on the high resolution mass spectra software predicted formulas with the reference compounds from the MS and MS^n^, the compounds **C23**, **C33**, **C36**, **C37**, **C38**, **C44**, **C46**, **C56**, **C58**, **C59**, **C49**, **C53**, **C60**, **C64**, and **C68** were identified as the reference compounds \[[@B11-molecules-19-05650],[@B13-molecules-19-05650]\].

**C27** has a RT at 30.773 min, \[M+HCOO\]^−^ at *m/z* 671.2155 in MS (predicted formula: C~29~H~38~O~15~: ppm error: −5.66), and characteristic fragment ions at *m/z* 625.2079 (−46 Da) \[M-H\]^−^, *m/z* 463.1589 \[M-162-H\], and *m/z* 301.1108 \[M-162-162-H\] in MS^2^. The neutral loss is mass 46 Da (CH~2~O~2~; identified as HCOOH), 162 Da\*2 (C~6~H~10~O~5~; identified as glucopyranoside), and the fragment ion *m/z* 301.1108 predicted as C~17~H~18~O~5~. Then C27 was identified as astraisoflavan-di-7-*O*-*β*-[d]{.smallcaps}-glucoside or its isomer. The \[M+H\]^+^ or \[M-H\]^−^ of **C24**, **C29**, **C30***,* and **C41** shows the same neutral loss of −162 Da (C~6~H~10~O~5~; glucoside) in them MS^2^, so both of them were identified as the glycosides \[[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B19-molecules-19-05650]\]. The characteristic fragment ions of **C31**, **C35**, **C43**, **C42**, and **C51** have a neutral loss of −248 Da (C~9~H~12~O~8;~ identified as the 6\'\'-*O*-malonate-glucoside) in them MS^2^, so both of them were identified as glycosides of 6\'\'-*O*-malonate-glucoside \[[@B13-molecules-19-05650]\].The HRM software predicted \[M+H\]^+^ or \[M-H\]^−^ of **C32**, **C40**, **C34**, **C47***,* and **C18***,* whose formulas have the same characteristic fragment loss (−204 Da; C~8~H~12~O~6~) which was identified as 6\'\'-*O*-acetylglucosides. In addition, **C32**, **C40**, **C34**, **C4**7, and **C18** were identified as glycosides of 6\'\'-*O*-acetylglucoside \[[@B16-molecules-19-05650]\].

For the predicted formulas of \[M+H\]^+^ or \[M-H\]^−^, we tentatively identified **C39**, **C50**, **C62**, **C30**, and **C41** as the isoflavonoid-related constituents by referring to the literature \[[@B18-molecules-19-05650],[@B19-molecules-19-05650]\], and **C45**, **C55**, **C48**, **C52**, **C54**, **C61**, and **C65** were tentatively identified as being related to saponins \[[@B13-molecules-19-05650],[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B19-molecules-19-05650]\].

Using the \[M+H\]^+^, \[M-H\]^−^ or \[M+Na\]^+^ data of **C7**, **C8**, **C10**, **C12**, **C13**, **C14**, **C21**, **C25**, **C26**, and **C28**, we predicted their formulas, which indicates that they are the ingredients of the samples. However, at this point, their exact structures could not be identified.

molecules-19-05650-t002_Table 2

###### 

The identified proposed compounds of the crude extract samples from Danggui Buxue Tang 1 and Danggui Buxue Tang 2 by HPLC-DAD-ESI-IT-TOF-MS^n^.

  NO.   T~R~ (min)   \[M+H\]^+^      \[M−H\]^−^    Predicted Formula     Fragment Ions Da      Error ppm   Identification                                                        DBT1      DBT2
  ----- ------------ --------------- ------------- --------------------- --------------------- ----------- --------------------------------------------------------------------- --------- ---------
  1     2.395                        173.1044      C~6~H~14~N~4~O~2~                           0.00        Arginine                                                              **C1**    **c1**
  2     2.692                        195.0502      C~6~H~12~O~7~                               −4.10       Gluconic acid                                                         **C2**    **c2**
  3     2.695                        341.1074      C~12~H~22~O~11~                             −4.40       [d]{.smallcaps}(+)sucrose                                             **C3**    **c3**
  4     3.643                        191.0187      C~6~H~8~O~7~          191,173               −5.24       Citric acid                                                           **C4**    **c4**
  5     4.477                        328.0427      C~11~H~11~N~3~O~9~                          1.22        \--                                                                   **C5**    **c5**
  6     6.480        346.0529                      C~11~H~11~N~3~O~10~                         3.47        \--                                                                   **C6**    **c6**
  7     9.063                        433.1364      C~18~H~26~O~12~       301,191               4.91        \--                                                                   **C7**    **\--**
  8     9.120        443.1146        \[M+Na\]^+^   C~17~H~24~O~12~                             −3.16       \-\-\--                                                               **\--**   **c7**
  9     9.345        267.1369                      C~18~H~18~O~2~        267,225               −4.12       Magnolol                                                              **\--**   **c8**
  10    9.398                        433.1364      C~18~ H~26~O~12~      433,351,301,223       2.77        \--                                                                   **C8**    **\--**
  11    10.773       188.0688                      C~9~ H~11~NO~2~       146                   3.19        L-phenylalanine                                                       **C9**    **c9**
  12    11.125                       431.1192      C~18~ H~24~O~12~      431,299               −0.70       \--                                                                   **C10**   **\--**
  13    12.653       384.1127                      C~13~H~21~NO~12~                            −2.60       \--                                                                   **C11**   **c10**
  14    13.840                       461.1283      C~19~H~26~O~13~       461,167               −3.90       \--                                                                   **\--**   **c11**
  15    13.847       485.1224        \[M+Na\]^+^   C~26~H~22~O~8~        485,317               3.50        \--                                                                   **C12**   **\--**
  16    17.807                       205.0701      C~8~H~14~O~6~                               −8.29       \--                                                                   **C13**   **\--**
  17    21.147                       315.2004      C~20~H~28~O~3~                              12.06       \--                                                                   **C14**   **\--**
  18    21.207                       433.1129      C~21~H~22~O~10~       433,285               −2.54       \--                                                                   **\--**   **c12**
  19    21.322                       433.1121      C~21~H~22~O~10~       433,285,241           −4.39       \--                                                                   **\--**   **c13**
  20    22.020                       417.1017      C~17~H~22~O~12~       417,285,152           -5.03       \--                                                                   **C15**   **c14**
  21    23.080       389.2325                      C~23~H~32~O~5~                              0.51        \--                                                                   **C16**   **c16**
  22    23.018                       401.1445      C~18~H~26~O~10~       401,269,161           −1.99       \--                                                                   **C17**   **c15**
  23    23.590                       503.1175      C~24~H~24~O~12~       503,443,299           −3.98       6\'\'-*O*-acetyl-pratensein-7-*O*-*β*-[d]{.smallcaps}-glucoside       **C18**   **\--**
  24    24.347                       239.0568      C~11~H~12~O~6~                              2.93        \--                                                                   **C19**   **\--**
  25    25.662       331.2296                      C~21~H~30~O~3~        331,299               8.45        \--                                                                   **C20**   **\--**
  26    26.743       470.1534                      C~18~H~23~N~5~O~10~                         3.40        \--                                                                   **C21**   **\--**
  27    26.967       289.1747                      C~13~H~24~N~2~O~5~    289,272,152           −3.80       \--                                                                   **C22**   **c17**
  28    30.653                       479.1492      C~30~H~24~O~6~        479,317               −1.67       \--                                                                   **C26**   **\--**
  29    30.773       \[M+HCOO\]^−^   671.2155      C~29~H~38~O~15~       671,625,463,301       −5.66       Astraisoflavan-di-7-*O*-*β*-[d]{.smallcaps}-glucoside                 **C27**   **\--**
  30    31.005                       579.2062      C~23~H~36~N~2~O~15~   579,417,387           3.28        \--                                                                   **C28**   **\--**
  31    31.348                       445.1123      C~22~H~22~O~10~       445,283               −3.82       Glycetein-4\'-*O*-*β*-[d]{.smallcaps}-glucoside                       **C29**   **\--**
  32    32.078       463.1203                      C~22~H~22~O~11~       463,301               −6.91       Kaempferide-7-*O*-*β*-[d]{.smallcaps}-glucoside                       **C30**   **\--**
  33    32.662       533.1267                      C~25~H~24~O~13~       533,285               −4.31       6\'\'-*O*-malonate-calycosin-7-*O*-*β*-[d]{.smallcaps}-glucoside      **C31**   **\--**
  34    34.207       489.1398                      C~24~H~24~O~11~       489,285               1.43        6\'\'-*O*-acetyl-calycosin-7-*O*-*β*-[d]{.smallcaps}-glucoside        **C32**   **\--**
  35    34.517       431.1322                      C~22~H~22~O~9~        431,269,237,118       −3.48       Ononin                                                                **C33**   **c18**
  36    35.348                       489.1340      C~24~H~26~O~11~       489,285,271,159       −12.68      6\'\'-*O*-acetyl-isosakuranetin-7-*O*-*β*-[d]{.smallcaps}-glucoside   **C34**   **\--**
  37    35.580       549.1174                      C~25~H~24~O~14~       549,301               −11.84      6\'\'-*O*-malonate-kaempferide-7-*O*-*β*-[d]{.smallcaps}-glucoside    **C35**   **\--**
  38    36.027       463.1615                      C~23~H~26~O~10~       485(+Na^+^),463,301   3.45        Astrapterocarpan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside            **C36**   **\--**
  39    36.773                       463.1577      C~23~H~28~O~10~       463,301,271           −7.13       Astraisoflavan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside              **C37**   **\--**
  40    37.480                       255.0657      C~15~H~12~O~4~        255,135               −2.35       Isoliquiritigenin                                                     **\--**   **c19**
  41    38.035       285.0744                      C~16~H~12~O~5~        285,270,225,137       −4.91       Calycosin                                                             **C38**   **c20**
  42    39.917                       269.0807      C~16~H~14~O~4~        269,253,227           −4.46       Isomer of alpinetin                                                   **\--**   **c21**
  43    39.977                       255.0657      C~15~H~12~O~4~        255,237               −2.35       Liquiritigenin                                                        **\--**   **c22**
  44    38.653       315.0844                      C~17~H~14~O~6~                              −6.03       4-methoxy-maackiain or the isomer                                     **C39**   **\--**
  45    38.653       473.1445                      C~24~H~24~O~10~       473,269               0.63        The isomer of 6\'\'-*O*-acetyl-ononin                                 **C40**   **\--**
  46    38.773       447.1264                      C~22~H~22~O~10~       447,285               −4.92       Glycetein-7-*O*-*β*-[d]{.smallcaps}-glucoside                         **C41**   **\--**
  47    38.997       549.1545                      C~26~H~28~O~13~       549,301               −10.56      6\'\'-*O*-malonate-astrapterocarpan-glucoside                         **C42**   **\--**
  48    39.452       517.1301                      C~25~H~24~O~12~       517,269               −7.73       6\'\'-*O*-malonate-ononin                                             **C43**   **\--**
  49    39.683                       505.1699      C~25~H~30~O~11~       505,301               −3.17       6\'\'-*O*-acetyl-astraisoflavan-7-*O*-*β*-[d]{.smallcaps}-glucoside   **C44**   **\--**
  50    39.745                       957.5030      C~48~H~78~O~19~       957,541,453           −3.66       Soyasaponin Ba                                                        **C45**   **c23**
  51    40.138       473.1424                      C~24~H~24~O~10~       473,269               −3.80       6\'\'-*O*-acetyl-ononin                                               **C46**   **\--**
  52    40.903                       927.4915      C~47~H~76~O~18~                             −4.74       Akebia saponin [d]{.smallcaps}                                        **\--**   **c24**
  53    40.430                       503.1154      C~24~H~24~O~12~       503,299               −8.15       6\'\'-*O*-acetyl-kaempferide-7-*O*-*β*-[d]{.smallcaps}-glucoside      **C47**   **\--**
  54    40.825                       785.4629      C~41~H~70~O~14~                             −8.15       Cyclocanthoside E                                                     **C48**   **\--**
  55    41.108                       991.5086      C~48~H~80~O~21~                             −3.33       Astragaloside V                                                       **C49**   **\--**
  56    41.273                       285.0751      C~16~H~14~O~5~        285,194,109           −5.96       Isomer of isosakuranetin                                              **\--**   **c25**
  57    41.772                       269.0456      C~15~H~10~O~5~        269,237               0.37        Genistein                                                             **\--**   **c26**
  58    41.778                       315.0868      C~17~H~16~O~6~        315,253               −1.90       Astragaluquinone or isomer                                            **C50**   **\--**
  59    41.950       533.1243                      C~25~H~24~O~13~       533,285               −8.82       6\'\'-*O*-malonate-glycetein-7-*O*-*β*-[d]{.smallcaps}-glucoside      **C51**   **\--**
  60    42.062                       867.4635      C~45~H~72~O~16~                             −13.03      Isoastragaloside I                                                    **C52**   **\--**
  61    42.243                       283.0602      C~16~H~12~O~5~        283,268,224           −3.53       Glycetein                                                             **\--**   **c27**
  62    42.612       \[M+HCOO\]^−^   829.4572      C~41~H~68~O~14~                             −2.29       Astragaloside IV                                                      **C53**   **\--**
  63    42.560                       825.4532      C~43~H~70~O~15~       871,825               −13.33      Isoastragaloside II                                                   **C54**   **\--**
  64    42.965                       329.2319      C~18~H~34~O~5~                              −4.25       \--                                                                   **\--**   **c28**
  65    43.197                       955.4857      C~48~H~76~O~19~                             −5.34       \--                                                                   **\--**   **c29**
  66    44.690                       287.0577      C~15~H~12~O~6~                              5.57        Dihydro-kaempferol                                                    **\--**   **c30**
  67    44.982                       255.0649      C~15~H~12~O~4~        256,135               −5.49       Isomer of Liquiritigenin                                              **\--**   **c31**
  68    45.315       269.0791                      C~16~H~12~O~4~        269,254,237,118       −6.32       Formononetin                                                          **C56**   **c32**
  69    44.190                       941.5081      C~48~H~78~O~18~       941,525,437           −3.61       Soyasaponin Bb                                                        **C55**   **c35**
  70    45.745       299.0911                      C~17~H~14~O~5~        299,284,166                       Pterocarpin                                                           **\--**   **c33**
  71    45.935                       329.2299      C~18~H~34~O~5~                              −10.33      \--                                                                   **C57**   **\--**
  72    46.080                       283.0599      C~16~H~12~O~5~        283,255,240           −4.59       The isomer of glycetein                                               **\--**   **c34**
  73    46.158       301.1052                      C~17~H~16~O~5~                              −6.31       Astraoptercarpan                                                      **C58**   **\--**
  74    46.708       303.1181                      C~17~H~18~O~5~                              −15.18      Astraisoflavan                                                        **C59**   **\--**
  75    46.768       \[M+HCOO\]^−^   871.4656      C~43~H~70~O~15~       871,825,603           −4.70       Astragaloside II                                                      **C60**   **\--**
  76    47.172       \[M+HCOO\]^−^   911.4668      C~45~H~70~O~16~       955,911               2.41        \--                                                                   **C61**   **\--**
  77    47.772                       299.0552      C~16~H~12~O~6~                              −3.01       Kaempferide or isomer                                                 **\--**   **c36**
  78    47.943                       909.4836      C~47~H~74~O~17~                             −1.87       Acetylastragaloside I                                                 **\--**   **c37**
  79    48.347       \[M+HCOO\]^−^   911.5011      C~46~H~74~O~15~                             0.11        Castaraleside H                                                       **\--**   **c38**
  80    49.432                       285.0423      C~15~H~10~O~6~        285,163               6.31        Kaempferol or isomer                                                  **C62**   **\--**
  81    50.065                       939.4925      C~48~H~76~O~18~                             −3.62       \--                                                                   **\--**   **c39**
  82    50.435       285.0748                      C~16~H~12~O~5~        285,253,152           −3.51       Isomer of calycosin                                                   **\--**   **c40**
  83    50.667       335.2180        \[M+Na\]^+^   C~18~H~32~O~4~                              −3.88       \--                                                                   **C63**   **c41**
  84    50.713       \[M+HCOO\]^−^   913.4777      C~45~H~72~O~16~                             −2.74       Astragaloside I                                                       **C64**   **\--**
  85    51.560       193.1212                      C~12~H~16~O~2~                              −5.70       Senkyunolide A                                                        **\--**   **c42**
  86    51.607       \[M+HCOO\]^−^   953.4637      C~47~H~72~O~17~       953,909               −12.06      \--                                                                   **C65**   **\--**
  87    52.363       437.3374        \[M+Na\]^+^   C~28~H~46~O~2~                              −3.66       \--                                                                   **C66**   **\--**
  88    55.212       191.1043                      C~12~H~14~O~2~                              −12.56      n-butyl-phthalide                                                     **\--**   **c43**
  89    59.250       213.0876        \[M+Na\]^+^   C~12~H~14~O~2~        403,213               −4.69       *Z*-ligustilide                                                       **C67**   **c44**
  90    61.708       403.1867        \[2M+Na\]+    C~12~H~14~O~2~        403,381,191           −3.22       *E*-ligustilide                                                       **C68**   **c45**
  91    69.093                       283.0257      C~15~H~8~O~6~         283,203,147           3.18        \--                                                                   **C69**   **c46**

![(**a**) The BPC in NI and PI mode of the crude extracts of Danggui Buxue Tang 1 (RA:RAS = 5:1). (**b**) The BPC in NI and PI mode of the crude extracts of Danggui Buxue Tang2 (RH:RAS = 5:1). (**c**) The BPC in NI and PI mode of the urine samples of rats that had been administrated the Danggui Buxue Tang 1 (RA:RAS = 5:1) and (**d**) The BPC in NI and PI mode of the urine samples of rats had been administrated the Danggui Buxue Tang 2 (RH:RAS = 5:1).](molecules-19-05650-g003){#molecules-19-05650-f003}

### 2.3.2. Identification of the Chemical Profiles of DBT2 by HPLC-DAD-ESI-IT-TOF-MS^n^

The HRMS data of these identified compounds are summarized (see [Table 2](#molecules-19-05650-t002){ref-type="table"} and Supplementary: pages S36--S51). The BPCs detected in NI and PI modes were recorded (see [Figure 3](#molecules-19-05650-f003){ref-type="fig"}b).

Using their fragment ions and retention times in MS data, **c18**, **c20**, **c32**, **c44**, and **c45** were identified as the reference compounds \[[@B11-molecules-19-05650],[@B13-molecules-19-05650]\].

Based the MS data, **c12** shows RT at 21.207 min, \[M-H\]^−^ at *m/z* 433.1129 in MS (predicted the formula: C~21~H~22~O~10~: ppm error: −2.54), and characteristic fragment ions at *m/z* 285.0744 (−148 Da; C~5~H~8~O~5~; identified as the ribonic acid) and predicted as C~16~H~14~O. Compound **c12** was identified as the isomer of isosakuranetin-ribonic acid. Moreover, **c13** shows a characteristic neutral loss at −148 Da (C~5~H~8~O~5~) with the same as **c12** \[[@B16-molecules-19-05650]\].

By the formulas predicted of \[M-H\]^−^ or \[M+H\]^+^ and referring to literature \[[@B13-molecules-19-05650],[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B19-molecules-19-05650]\], **c23**, **c24**, **c29**, **c35**, **c38**, and **c39** were tentatively identified as saponin-related constituents, and **c7**, **c8**, **c11**, **c19**, **c21**, **c22**, **c25**, **c26**, **c27**, **c31**, **c33**, **c34**, **c36**, **c40**, and **c43** were tentatively identified (see in [Table 2](#molecules-19-05650-t002){ref-type="table"}).

By using the HRMS data (RT, Predicted the formulas and characteristic fragment ions) compared with the BDT1 crude extract samples, **C1**, **c1**; **C2**, **c2**; **C3**, **c3**; **C4**, **c4**; and **C9**, **c9** were identified as the same constituents \[[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B19-molecules-19-05650]\].

The groups of **C5**, **c5**; **C6**, **c6**; **C11**, **c10**; **C15**, **c14**; **C16**, **c16**; **C17**, **c15**; **C22**, **c17**; **C57**, **c28**; **C63**, **c41**; and **C69**, **c46** between DBT1 and DBT2 were tentatively identified as the same compounds with uncertain structures.

From the analysis based on the comparison of TIC and MS^n^: 69 compounds (**C1--C69**) were identified from the crude extracts of DBT1, 46 compounds (**c1--c46**) were identified from the crude extracts of DBT2. The isoflavonoids glycosides had experienced acetylation (seven compounds, **C18**, **C32**, **C34**, **C40**, **C44**, **C46**, and **C47**), formed the malonate acid esters (five compounds, **C31**, **C35**, **C42**, **C43**, and **C51**) and with special astragalosides (six compounds, **C49**, **C52**, **C53**, **C54**, **C60**, and **C64**) in DBT1. Thus, the number of identified components in DBT1 was significantly more than in DBT2 (the chemical structural diversity of isoflavonoids which were detected in DBT1 more than in DBT2 are shown in [Figure 4](#molecules-19-05650-f004){ref-type="fig"}). Among these, the 24 common chemical constituents accounted for approximately 27% to the total 91 identified compounds. However, and the proportion of the total isoflavonoids and saponins to the total identified ingredients accounted for nearly 62% (see [Table 3](#molecules-19-05650-t003){ref-type="table"}).

![The chemical structures of the main proposed different isoflavonoids in Danggui Buxue Tang 1 more than Danggui Buxue Tang 2.](molecules-19-05650-g004){#molecules-19-05650-f004}

molecules-19-05650-t003_Table 3

###### 

The number comparison of the identified compounds between Danggui Buxue Tang 1 and Danggui Buxue Tang 2.

  N.       ID.   S-ID.   T.ID.         S%      H + S   S%
  -------- ----- ------- ------------- ------- ------- -------
  DBT1     69    24      115−24 = 91   26.37   56      61.54
  DBT2     46                                          
  DBT1-U   44    19      78−19 = 59    32.20   48      81.35
  DBT2-U   34                                          

ID. Total identified proposed compounds number; S-ID. Identified the common proposed compounds number between two Danggui Buxue Tangs; T.ID. Identified the unfamiliar proposed compounds number between two Danggui Buxue Tangs; H + S: The total isoflavones and the total saponins number; S% The ratio about the selective compounds in the total identified proposed compounds number.

2.4. Profiling and Identifying Chemical Profiles of the Urine Samples after Administration of the DBT1 and DBT2 Performed by HPLC-DAD-ESI-IT-TOF-MS^n^
------------------------------------------------------------------------------------------------------------------------------------------------------

In the study of the existing literature, ingredients such as isoflavones, saponins in the two DBTs had no obvious differences in chemical profiles between the serum and bile samples collected from enterohepatic circulation. In addition, they had a lower concentration in serum samples, even when giving at dosages of 60--120 g/kg (w/w) several times to rats within 24 h \[[@B13-molecules-19-05650],[@B17-molecules-19-05650],[@B20-molecules-19-05650]\]. Thus, this approach is not conducive to tracing these minor components. This study chose the normal usage of 10 g/kg (w/w) by comparing the urine samples of rats that were administrated two different DBTs, so as to improve the detection through enrichment of the treatments.

### 2.4.1. Identification of the Chemical Profiles of Urine Sample after Administration of the DBT1 by HPLC-DAD-ESI-IT-TOF-MS^n^

The HRMS data of these identified metabolites are summarized (see [Table 4](#molecules-19-05650-t004){ref-type="table"} and [Supplementary: pages S52--S66](#app1-molecules-19-05650){ref-type="app"}). The BPCs detected in NI mode were recorded (see [Figure 3](#molecules-19-05650-f003){ref-type="fig"}c). In addition, the main proposed structures of these metabolites identified from the urine samples of rats that had been administrated DBT1 were showed (see [Figure 5](#molecules-19-05650-f005){ref-type="fig"}).

Using MS data with the reference compounds, **M15** was identified as calycosin, and **M23** was identified as formononetin \[[@B11-molecules-19-05650],[@B13-molecules-19-05650]\].

With the predictions of \[M-H\]^−^ or \[M+HCOO\]^−^, and the characteristic fragment ions, **M9**, **M7**, **M19**, **M8**, **M10**, **M11**, **M13**, **M14**, **M22**, **M16**, **M18**, **M20**, **M21**, **M24**, **M32**, and **M36** were tentatively identified as the metabolites of isoflavonoids \[[@B13-molecules-19-05650],[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B19-molecules-19-05650],[@B21-molecules-19-05650]\].

**M25** shows RT at 46.290 min, \[M+H\]^+^ at *m/z* 335.0201 in MS (predicted formula: C~15~H~10~O~7~S: ppm error: −5.67), and characteristic fragment ions at *m/z* 255.0637 (−80 Da; SO~3~; identified as the sulfonyl hydroxide) and predicted as C~15~H~10~O~4.~ Then M25 was identified as daidzein after sulfation. **M27**, **M26**, **M34**, **M28**, **M29**, **M30**, **M31**, **M33**, **M35**, **M37**, **M38**, **M43**, and **M44** have the same neutral loss of −80 Da, which was identified as the sulfonyl hydroxide (SO~3~), so they were identified as the sulfated products \[[@B13-molecules-19-05650],[@B16-molecules-19-05650]\].

When predicting their formulas, **M39**, **M41**, and **M42** were identified as related metabolites of saponins \[[@B13-molecules-19-05650],[@B17-molecules-19-05650]\].

molecules-19-05650-t004_Table 4

###### 

The identified proposed metabolites from the urine samples of rats that had been administrated Danggui Buxue Tang1 and Danggui Buxue Tang 2.

  NO.   T~R~ (min)   \[M+H\]^+^      \[M-H\]^−^    Predicted Formula    Fragment Ions   Error ppm   Identification                                             DBT1      DBT2
  ----- ------------ --------------- ------------- -------------------- --------------- ----------- ---------------------------------------------------------- --------- ---------
  1     4.132                        287.0065      C~10~H~8~O~10~                       6.97        \--                                                        **M1**    **m1**
  2     28.200                       231.0768      C~12~H~12~N~2~O~3~   463,231         −3.03       \--                                                        **M2**    **m2**
  3     29.298                       233.0115      C~12~H~2~N~4~O~2~    233,169         4.29        \--                                                        **M3**    **m3**
  4     29.298                       337.1408      C~16~H~22~N~2~O~6~   337,253         0.89        \--                                                        **M4**    **m4**
  5     31.083       268.1164        266.1021      C~13~H~17~NO~5~                      −4.89       \--                                                        **\--**   **m5**
  6     31.338                       275.0209      C~13~H~8~O~7~        275,195         4.36        \--                                                        **M5**    **m6**
  7     32.927                       273.0056      C~13~H~6~O~7~        273,193         5.49        \--                                                        **M6**    **m7**
  8     33.038       271.0585                      C~15~H~10~O~5~                       −5.90       Hydroxydaidzein                                            **M7**    **\--**
  9     34.518       \[M+HCOO\]^−^   475.1244      C~22~H~22~O~9~       475,267         −0.42       Isomer of ononin                                           **\--**   **m8**
  10    36.155                       303.0863      C~16~H~16~O~6~       303,151         −3.63       Hydroxylcalycosin, direduction(C^2^=C^3^; C^4^=O)          **M8**    **\--**
  11    36.705                       253.0492      C~15~H~10~O~4~                       −5.53       Daidzein                                                   **M9**    **m9**
  12    36.808                       477.1372      C~23~H~26~O~11~      477,301         −6.29       Astraisoflavan, glucuronidation                            **M10**   **\--**
  13    36.868                       255.0662      C~15~H~12~O~4~       255,149         −0.39       Daidzein, reduction(C^2^=C^3^)                             **M11**   **m10**
  14    37.255       385.1478                      C~18~H~24~O~9~                       −3.89       Hydroligustilide, glucuronidation                          **M12**   **\--**
  15    37.442                       255.0655      C~15~H~12~O~4~                       −3.14       Daidzein, reduction(C^4^=O)                                **\--**   **m11**
  16    37.502                       285.0751      C~16~H~14~O~5~       285,269,149     −5.96       Calycosin, reduction(C^2^=C^3^)                            **M13**   **m12**
  17    37.195                       257.0809      C~15~H~14~O~4~                       −3.89       Daidzein, direduction(C^2^=C^3^; C^4^=O)                   **M14**   **\--**
  18    38.033                       283.0608      C~16~H~12~O~5~       283,268         −1.41       Calycosin                                                  **M15**   **m13**
  19    38.362                       285.0751      C~16~H~14~O~5~       285,270         −5.96       Calycosin, reduction(C^4^=O)                               **M16**   **\--**
  20    39.047                       273.0761      C~15~H~14~O~5~       273,240,109     −2.56       Hydroxydaidzein, direduction (C^2^=C^3^; C^4^=O)           **\--**   **m14**
  21    39.367                       233.0098      C~12~H~2~N~4~O~2~                    −3.00       \--                                                        **M17**   **m15**
  22    40.260       \[M+HCOO\]^−^   363.0748      C~16~H~14~O~7~                       7.16        Dihydroxycalycosin, reduction(C^2^=C^3^)                   **M18**   **\--**
  23    41.630                       283.0609      C~16~H~12~O~5~       283,268,224     −1.06       Isomer of calycosin                                                  **m16**
  24    41.755                       269.0441      C~15~H~10~O~5~                       −5.20       Hydroxydaidzein                                            **M19**   **\--**
  25    42.180                       283.0603      C~16~H~12~O~5~       283,268,224     −3.18       Isomer of calycosin                                        **\--**   **m17**
  26    42.365                       299.0554      C~16~H~12~O~6~       299,284         −2.34       Hydroxycalycosin, or isomer                                **M20**   **\--**
  27    42.923                       299.0556      C~16~H~12~O~6~       299,284         −1.67       Hydroxycalycosin                                           **M21**   **\--**
  28    44.315                       257.0819      C~15~H~14~O~4~                       0.00        Isoliquiritigenin, reduction(C=C)                          **M20**   **m18**
  29    45.322       269.0796                      C~16~H~12~O~4~       269,253,237     −4.46       Formononetin                                               **M23**   **m19**
  30    45.733                       269.0804      C~16~H~14~O~4~       269,254,135     −5.57       Formononetin, reduction(C^2^=C^3^)                         **M24**   **m20**
  31    46.290       335.0201                      C~15~H~10~O~7~S      335,255         −5.67       Daidzein, sulfation                                        **M25**   **m21**
  32    47.775                       299.0556      C~16~H~12~O~6~       299,256         −1.67       Hydroxycalycosin                                           **\--**   **m22**
  33    47.862                       363.0174      C~16~H~12~O~8~S      363,268         −1.65       Calycosin, sulfation                                       **M26**   **\--**
  34    47.922                       333.0059      C~15~H~10~O~7~S      333,253,225     −4.50       Daidzein, sulfation                                        **M27**   **\--**
  35    48.747                       365.0347      C~16~H~14~O~8~S      365,285         2.74        Calycosin, reduction(C^2^=C^3^), sulfation                 **M29**   **\--**
  36    49.072                       333.0056      C~15~H~10~O~7~S      333,253,208     −5.41       Daidzein, sulfation                                        **\--**   **m23**
  37    49.543                       333.0059      C~15~H~10~O~7~S      333,253         −4.50       Isomer of daidzein, sulfation                              **\--**   **m24**
  38    49.193                       365.0360      C~16~H~14~O~8~ S     365,285         6.30        Calycosin, reduction(C^2^=C^3^), sulfation                 **M30**   **\--**
  39    49.810                       349.0033      C~15~H~10~O~8~S      349,269,225     2.58        Hydroxydaidzein, sulfation                                 **M28**   **m25**
  40    49.623                       351.0187      C~15~H~12~O~8~S      351,271,149     1.99        Hydroxydaidzein, reduction(C^2^=C^3^), sulfation           **M31**   **\--**
  41    50.325                       337.0395      C~15~H~14~O~7~S      337,257         2.37        Daidzein, direduction(C^2^=C^3^; C^4^=O), sulfation        **\--**   **m27**
  42    50.467                       283.0595      C~16~H~12~O~5~       283,268         −6.01       Isomer of calycosin                                        **M32**   **\--**
  43    50.973                       367.0483      C~16~H~16~O~8~S      367,272,150     −2.72       Calycosin, direduction(C^2^=C^3^; C^4^=O), sulfation       **M33**   **\--**
  44    51.515                       363.0180      C~16~H~12~O~8~S      363,283         0.00        Calycosin, sulfation                                       **M34**   **m26**
  45    52.563                       335.0250      C~15~H~12~O~7~S      335,255,135     5.67        Daidzein, reduction(C^2^=C^3^), sulfation                  **M35**   **\--**
  46    53.637                       343.0835      C~18~H~16~O~7~                       3.50        \--                                                        **M36**   **\--**
  47    55.693                       351.0172      C~15~H~12~O~8~S      351,271         −2.28       Hydroxydaidzein, reduction(C^2^=C^3^), sufaltion           **\--**   **m28**
  48    55.165                       321.0417      C~15~H~14~O~6~S      321,241         −6.54       Equol, sulfation                                           **M37**   **m29**
  49    59.468                       337.0388      C~15~H~14~O~7~S      337,257,243     0.30        Daidzein, direduction(C^2^=C^3^; C^4^=O), sulfation        **M38**   **\--**
  50    59.728       619.3669        \[M+Na\]^+^   C~36~H~52~O~7~                       10.33       Related to astragaloside                                   **\--**   **m30**
  51    61.838       683.4277                      C~35~H~64~O~11~                      −9.57       Related to astragaloside                                   **M39**   **\--**
  52    62.002       639.4061                      C~35~H~58~O~10~                      −6.57       Related to astragaloside                                   **M40**   **\--**
  53    62.113       595.3742                      C~33~H~54~O~9~                       −16.63      Related to astragaloside                                   **M41**   **m31**
  54    63.292                       509.3599      C~33~H~50~O~4~                       −7.26       Related to astragaloside                                   **\--**   **m32**
  55    62.414       507.3296                      C~29~H~46~O~7~                       −3.94       Related to astragaloside                                   **M42**   **\--**
  56    71.557                       353.0324      C~15~H~14~O~8~S      353,273         −3.68       Hydroxydaidzein, direduction(C^2^=C^3^;C^4^=O) sulfation   **M43**   **\--**
  57    71.557                       397.0250      C~16~H~14~O~10~S     397,317         3.78        Dihydroxycalycosin, reduction(C^2^=C^3^), sulfation        **M44**   **\--**
  58    72.797                       363.0197      C~16~H~12~O~8~S      363,283         4.68        Calycosin, sulfation                                       **\--**   **m33**
  59    73.543                       347.0213      C~16~H~12~O~7~S      347,267         −5.19       Formononetin, sulfation                                    **\--**   **m34**

![The main proposed metabolites identified from the urine samples of rats that had been administrated Danggui Buxue Tang 1.](molecules-19-05650-g005){#molecules-19-05650-f005}

### 2.4.2. Identification of the Chemical Profiles of Urine Sample after Administration of the DBT2 by HPLC-DAD-ESI-IT-TOF-MS^n^

The HRMS data of these identified metabolites are summarized (see [Table 4](#molecules-19-05650-t004){ref-type="table"} and [Supplementary: pages S67--S77](#app1-molecules-19-05650){ref-type="app"}). The BPCs detected in NI model were recorded (see in [Figure 3](#molecules-19-05650-f003){ref-type="fig"}d). The main proposed structures of metabolites identified from the urine samples of rats that had been administrated DBT2 were showed (see [Figure 6](#molecules-19-05650-f006){ref-type="fig"}).

The MS data of **m13**, and **m19** show that they are the reference compounds. In addition, **m13** was identified as calycosin, and **m19** was identified as formononetin \[[@B11-molecules-19-05650],[@B13-molecules-19-05650]\].

Moreover, **m8** has a RT at 34.518 min, \[M+HCOO\]^−^ at *m/z* 475.1244 in MS (predicted formula: C~22~H~22~O~9~: ppm error: −0.42), and characteristic fragment ions at *m/z* 267.0656 that are predicted as C~16~H~12~O~4~, the neutral loss is 46 Da (HCOOH) + 162 Da (C~6~H~10~O~5~; identified as glucoside). Thus, **m8** was identified as the isomer of ononin \[[@B13-molecules-19-05650]\].

In their MS and MS^2^ Data, **m21**, **m23**, **m22**, m24, **m25**, **m26**, **m33**, **m27**, **m28**, **m29**, and **m34** have the same neutral loss of −80 Da, which was predicted as the sulfonyl hydroxide (SO~3~), so they were identified as the sulfated products \[[@B13-molecules-19-05650],[@B16-molecules-19-05650]\].

![The main proposed metabolites identified from the urine samples of rats that had been administrated Danggui Buxue Tang 2.](molecules-19-05650-g006){#molecules-19-05650-f006}

By the MS data of \[M-H\]^−^ or \[M+HCOO\]^−^ and the characteristic fragment ions, **m9**, **m10**, **m11**, **m12**, **m14**, **m16**, **m17**, **m18**, and **m20** were identified as the metabolites of isoflavonoids \[[@B13-molecules-19-05650],[@B14-molecules-19-05650],[@B15-molecules-19-05650],[@B17-molecules-19-05650],[@B18-molecules-19-05650],[@B21-molecules-19-05650]\]. Using their predictions of \[M+Na\]^+^ or \[M+H\]^+^, **m30**, **m31**, and **m32** were tentatively identified as saponin-related metabolites \[[@B13-molecules-19-05650],[@B17-molecules-19-05650]\].

Between DBT1 and DBT2, the groups **M1**, **m1**; **M2**, **m2**; **M3**, **m3**; **M4**, **m4**; **M5**, **m6**; **M6**, **m7**; and **M15**, **m17** were identified as the same compounds, respectively.

In this part of the experiment, decoctions of DBT1 and DBT2 were administered to rats, and an analysis was conducted on the rats' urine for metabolites: 44 compounds (**M1--M44**) were identified from the urine samples after DBT1 was administrated, 34 compounds (**m1--m34**) were identified from the urine samples after DBT2 was administrated. The number of the chemical components in the urine samples from DBT1 was administrated to rats are slightly more than these of DBT2. The proportion of the 19 common constituents to the total 59 identified compounds accounted for approximately 33%. The proportion of 48 total isoflavonoids and saponins to the total identified compounds, however, reached approximately 82% (See [Table 3](#molecules-19-05650-t003){ref-type="table"}).

The phase Ⅱ metabolites from the urine samples of DBT1 and DBT2 were dominantly sulfated products, with rare or no glucuronide metabolites. This result still requires further research as the literature reports the chief presence of mainly glucuronide metabolites \[[@B13-molecules-19-05650],[@B14-molecules-19-05650],[@B15-molecules-19-05650],[@B16-molecules-19-05650]\]. Metabolites that originated from RAS are relatively rare or not detected. This is likely due to the low proportion of RAS in DBT and even the low dosage that was given to rats in this study, those chemical constituents of RAS being easy to volatilize, or a loss when sampling was conducted by concentrated processes \[[@B22-molecules-19-05650],[@B23-molecules-19-05650]\]. At this normal dosage of DBT and due to poor absorption, the content levels of astragalosides are much lower. In addition, saponins and their metabolites that originated from astragalosides are rarely detected \[[@B24-molecules-19-05650],[@B25-molecules-19-05650],[@B26-molecules-19-05650],[@B27-molecules-19-05650]\].

The HPLC-DAD-ESI-IT-TOF-MS*^n^* method adopted in our research was confirmed to be a powerful method to evaluate the chemical profiles of the crude extracts and the related urine samples. As we know, the chemical composition found in a Chinese herbal decoction is rather complicated. In this study, the chemical profile analysis of DBT1 and DBT2 was conducted, which provided a comprehensive understanding of that those isoflavonoids that play an important role in the main common chemical basis when they are used in clinical practice. Some identified metabolites are known to have many bioactivities, such as calycosin, formononetin, daidzein and equol (which are well-known phytoestrogens), and most of them displayed many beneficial effects to humans \[[@B28-molecules-19-05650],[@B29-molecules-19-05650],[@B30-molecules-19-05650]\].

Through the comparison of chemical profiles of two DBTs at our used normal dosage, the similarity of urine samples is higher than that of the crude extract samples. This leads us to believe that the main chemical basis of the chemical constituents is almost the same. Whether the DBT2 of RH:RAS can replace the DBT1 of RA:RAS, we need to further investigate different ratios of RH:RAS with the RA: RAS (5:1) when using equivalent pharmacological research.

3. Experimental
===============

3.1. Materials and Reagents
---------------------------

Radix Astragali was collected from Shanxi Province (Voucher No. 130401, Specimen No. 1167), Radix Hedysari was collected from Neimeng Province (Voucher No. 130401, Specimen No. 1168) and Radix Angelica sinensis was collected from Gansu Province (Voucher No. 130401, Specimen No. 1169). All of those medicinal materials were purchased from Guangzhou Zixing Herbal Company in Guangzhou at June in 2013 by Liu Jing and they are identified by Prof. Chen Hu-Biao. The following reference compounds: (6aR,11aR)-3-hydroxy-9,10-dimethoxypterocarpan (astrapterocarpan), ononin, formononetin, 6\'\'-*O*-acetyl-ononin, calycosin, ferulic acid, (3R)-7,2\'-dihydroxy-3\',4\'-dimethoxyisoflavan (astraisoflavan), calycosin-7-*O*-*β*-[d]{.smallcaps}-glucoside, astrapterocarpan-7-*O*-*β*-[d]{.smallcaps}-glucoside, *Z*-ligustilide, *E*-ligustilide, astragaloside I, astragaloside II, astragaloside III, astragaloside IV, astragaloside V, astraisoflavan-7-*O*-*β*-[d]{.smallcaps}-glucoside and 6\'\'-*O*-acetyl-astraisoflavan-7-*O*-*β*-[d]{.smallcaps}-glucoside were prepared and identified in our preliminary work \[[@B10-molecules-19-05650],[@B11-molecules-19-05650],[@B12-molecules-19-05650],[@B13-molecules-19-05650],[@B14-molecules-19-05650]\]. Acetonitrile (Merck Co., Darmstadt, Germany) and formic acid (Mreda Technology Inc., Beijing, China) were of HPLC grade. Ultra-pure water was prepared by a Milli-Q water purification system (Millipore, Billerica, MA, USA).

3.2. Sample Preparation
-----------------------

In clinical use, DBT is typically boiled with water twice, then the two decoctions are combined and applied \[[@B1-molecules-19-05650]\]. Therefore, in our study, DBT1, consisting of RA 100 g and RAS 20 g was boiled in 1,000 mL of water (w:v) for 45 min, and then the decoction was filtered. The residue was again boiled in 700 mL of water (w:v) for 30 min. The two decoctions were evaporated to dryness under reduced pressure at 50 °C to 100 mL volume. Samples of DBT2, consisting of RH 100 g and RAS 20 g, were prepared in the same way.

3.3. Animals and Administration
-------------------------------

12 male Sprague-Dawley (SD) rats (220--250 g) were provided by the Experimental Animal Center of Peking University Health Science Center (Beijing, China) and divided into two groups. They were housed in metabolic cages (Type: DXL-DL, Suzhou Fengshi Laboratory Animal Equipment Co. Ltd., Suzhou, China), and kept in an environmentally controlled breeding room for one-week acclimation. Throughout the experiments, rats had unrestricted access to laboratory chow and water. The DBT1 and DBT2 were administrated by oral at a dose of raw medicinal material 10 g/kg body weight once a day (at 17:30 pm) respectively. Totally for 2 days. All procedures used in the animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the US National Institute of Health. The experiments were reviewed by the Biomedical Ethical Committee of Peking University (Approval No. LA2013-193).

3.4. Urine Sample Collection and Pretreatment
---------------------------------------------

Urine samples in each group (n = 6) were collected during the first 48 h after administration of the drugs began(Blank urine collected by self-control.); Finally, all urine samples from the same group were merged into one sample, then dried under vacuum at 50 °C using a Heidolph Laborota 4001 rotatory evaporator (Heidolph Instruments GmbH & Co., Schwabach, Germany), and then 1.00 g of the dried samples were reconstituted in 10 mL methanol, followed by 30 min ultrasonic extraction and 15 min centrifugation at 5,000 rpm. Afterward, the supernatant was collected for detection.

3.5. Instrumentations and Conditions
------------------------------------

HPLC analysis was performed on a Shimadzu HPLC (Shimadzu, Kyoto, Japan) equipped with two LC-20AD pumps, aCTO-20A column oven, an SIL-20AC autosampler, an SPD-M20A PDA detector and a CBM-20A system controller. The chromatographic separation was carried out on a Phenomenex Gemini C~18~ column (250 × 4.6 mm, 5 μM) protected with a Phenomenex Security Guard column (4 × 3.0 mm, 5 μM) (Phenomenex, Torrance, CA, USA). For each sample, an aliquot of 20 μL was injected with needle wash. The thermostatted auto-sampler was maintained at 15 °C; column oven temperature was kept at 30 °C. The column was eluted with a gradient mobile phase consisted of water-formic acid (100:0.1, v/v) (A) and acetonitrile (B) at the flow rate of 1.0000 mL/min. Gradient program was adopted in the following manner: 5% B at 0--10 min, 5%--15% B at 10--20 min, 15%--40% B at 20--40 min, 40%--65% B at 40--55 min, 65%--100% B at 55--65 min, 100% B at 65--75 min, 5% B at 75--85 min.

High resolution mass spectra were recorded on an IT-TOF mass spectrometer (Shimadzu). The ESI source was operated both in negative and positive ion mode. The mass spectrometry was programmed to carry out full scan over *m/z* 100--1000 Da (MS^1^), *m/z* 50--1000 Da (MS^2^ and MS^3^). A trifluoroacetic acid sodium solution (2.5 mM) was used to calibrate the mass range from 50 to 1000 Da. The other parameters were set as follows: flow rate, 0.20 mL/min (split from 1.00 mL/min HPLC effluent); heat block and curved desolvation line temperature, 200 °C; nebulizing nitrogen gas flow, 1.5 L/min; interface voltage: (+), 4.5 kV; (−), −3.5 kV; detector voltage, 1.70 kV; relative collision-induced dissociation energy (50%) \[[@B15-molecules-19-05650]\].

3.6. Data Analysis
------------------

All data were recorded and processed by Shimadzu software LCMS solution version 3.60, Formula Predictor version 1.2 and Accurate Mass Calculator (Shimadzu).

4. Conclusions
==============

A comparison was conducted on the similarities and differences of crude extracts and urine samples of DBT1 and DBT2. The chemical profiles of the crude extracts comprised a total of 115 proposed chemical components. There were 24 common ingredients, which was accounted for 27% in the total 91 identified components. There were a total of 56 isoflavonoids and saponins identified, which accounted for nearly 62% in the total identified components. Since isoflavonoid glycosides had acetylation (**C18**, **C32**, **C34**, **C40**, **C44**, **C46**, and **C47**), the formation of malonate acid esters (**C31**, **C35**, **C43**, **C42**, and **C51**) and special astragalosides (**C49**, **C52**, **C53**, **C54**, **C60**, and **C64**) in DBT1, the identified compounds from DBT1 were significantly greater than DBT2. Of these, **C18**, **C34**, **C35**, **C42**, **C47**, and **C51** were identified from DBT for the first time.

In total, 78 proposed chemical components in the urine samples of rats that had been administrated DBT1 and DBT2, respectively, were found. These included 19 common ingredients, which accounted for approximately 33% in the total identified constituents. In addition, 48 of total isoflavonoids and saponins were found, which accounted for nearly 82% of the total 59 identified components. The differences between those metabolites in the urine samples were revealed to be less than the crude extracts. These identified metabolites are mainly originated from formononetin, calycosin and their related glycosides, which are formed mainly through the metabolic processes of reduction, deglycosylation, demethylation, hydrogenation and sulfation. Through the comparison of chemical profiles of two DBTs at our used doses, the similarity of urine samples is higher than that of the crude extract samples, one can think the main chemical constituents are almost the same as when administrated to rats.

The HPLC-DAD-ESI-IT-TOF-MS^n^ method was successfully applied for the chemical profile comparison of two different DBTs and its related medicinal materials. The proposed assay provides an important reference and can be a suitable method for the rapid and accurate chemical basis evaluation of TCM or their related prescriptions.
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